Antibiotic overuse is a key driver in the rise of antimicrobial resistance (AMR), a major global health crisis.

Houston Methodist researchers have identified a key protein as a potential therapeutic target for stopping the body's immune ...

Atara Biotherapeutics (ATRA) announced that the FDA has placed a clinical hold on Atara’s active investigational new drug, or IND, ...

Objective Evaluating the potential role of neuromuscular ultrasonography (NMUS) in assessing optic nerve affection in ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter ...

Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...

It takes courage to be our genuine selves, writes columnist Candace Semien, who shares a couple powerful prayers for lupus.

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for amyotrophic ...

Study reveals fibromyalgia impacts nearly 20% of lupus patients, reducing quality of life and calling for improved diagnosis ...

Caribou Biosciences has launched a Phase 1 trial testing its CAR T-cell therapy CB-010 for lupus affecting the kidneys and ...